Dr. Mark A. Taylor, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Jefferson Medical College of Thomas Jefferson University (1996)
- Years since graduation
- 30
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 691
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1996Medical school: Jefferson Medical College of Thomas Jefferson University
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
GA license 045130 · SC license 22960
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Candler Hospital Savannah, GA
- St Joseph's Hospital - Savannah Savannah, GA
- Effingham Health System Springfield, GA
Medical groups
- Candler Medical Oncology Practice LLC (27 clinicians)
- Effingham Physician Practices, LLC (4 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 691
- Services billed
- 2,832
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 920 | 481 |
| Established patient office or other outpatient visit, 30-39 minutes | 838 | 286 |
| Established patient office or other outpatient visit, 40-54 minutes | 128 | 77 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 62 | 38 |
| New patient office or other outpatient visit, 60-74 minutes | 58 | 58 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 49 | 35 |
| New patient office or other outpatient visit, 45-59 minutes | 31 | 31 |
| Telephone medical discussion with physician, 11-20 minutes | 29 | 25 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | 20 | 14 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 17 | 17 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in Savannah, GA | 207 |
| Letrozole Other prescribers in Savannah, GA | 52 |
| Calquence (acalabrutinib maleate) | 39 |
| Eliquis (apixaban) Other prescribers in Savannah, GA | 37 |
| Prednisone Other prescribers in Savannah, GA | 36 |
| Lenalidomide | 35 |
| Pomalyst (pomalidomide) | 34 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Savannah, GA | 33 |
| Ibrance (palbociclib) | 29 |
| Imbruvica (ibrutinib) | 24 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 25 companies reported 68 payments worth $1,271 in total to this clinician.
| Novartis Pharmaceuticals Corporation | $159 |
|---|---|
| Merck Sharp & Dohme LLC | $145 |
| AbbVie Inc. | $112 |
| Janssen Biotech, Inc. | $86.07 |
| Regeneron Healthcare Solutions, Inc. | $67.71 |
| E.r. Squibb & Sons, L.l.c. | $65.02 |
| Kite Pharma, Inc. | $64.18 |
| Incyte Corporation | $62.04 |
| Food and Beverage | $1,271 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 12 industry-funded studies in 2025, from 5 companies. The companies reported $1,857,081 in research payments for these studies, mostly to the institutions running them.
- An interventional openlabel randomized multicenter phase 3 study of PF07220060 plus letrozole compared to CDK46 inhibitor plus letrozole in participants over 18 years of age with hormone receptor hrpositive HER2NEGATI…
Pfizer Inc. - A Phase IIIb Study to Characterize the Effectiveness and Safety of Adjuvant Ribociclib in a Wide Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER)
Novartis Pharmaceuticals Corporation - An openlabel multicenter randomized phase 3 study of firstline encorafenib plus cetuximab with or without chemotherapy versus standard of care therapy with a safety leadin of encorafenib and cetuximab plus chemotherap…
Pfizer Inc. - A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
Eli Lilly and Company · Active, not recruiting · NCT05514054 - A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Eli Lilly and Company · Recruiting · NCT05254743 - The COMPASSHER2 trials comprehensive use of pathologic response assessment to optimize therapy in HER2POSITIVE breast cancer COMPASSHER2 residual disease rd a doubleblinded phase iii randomized trial of TDM1 compared …
Pfizer Inc. - An interventional openlabel randomized multicenter phase 3 study of PF07220060 plus fulvestrant compared to investigators choice of therapy in participants over 18 years of age with hormone receptorpositive HER2NEG…
Pfizer Inc. - Connect MM: The Multiple Myeloma Disease Registry. The purpose of the Connect MM Registry is to explore the natural history and real world management of patients with newly diagnosed symptomatic multiple myeloma (MM) …
E.r. Squibb & Sons, L.l.c. - Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC
Genentech, Inc. - Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
Eli Lilly and Company · Active, not recruiting · NCT03155997
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.